CombinatoRx Diabetes Drug Shows Promise


CombinatoRx (NASDAQ:CRXX) reports that its Type 2 diabetes treatment, a combination of bezafibrate and diflunisal, provided statistically significant reduction in blood sugar levels and other benefits in a mid-stage clinical trial. It’s a bit of good news for Cambridge, MA-based CombinatoRx after it revealed last October that its lead arthritis drug failed in a Phase II trial.

By posting a comment, you agree to our terms and conditions.